nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

12.07.2018 | Head & Neck

Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors

verfasst von: Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Salivary gland tumors are complex and have a great histomorphological diversity; more than 30 histological subtypes are currently described and the study of proteins that help understand and differentiate these tumors is essential. We aimed to analyze the immunoexpression of cyclooxygenase-2 (COX-2) and cyclin D1 proteins in pleomorphic adenomas (PA), mucoepidermoid carcinomas (MEC) and adenoid cystic carcinomas (AdCC) of salivary glands.

Methods

A total of 38 PA, 12 AdCC and 12 MEC underwent immunohistochemical study by the polymeric biotin-free technique. Immunopositive cells were analyzed semi-quantitatively. For statistical analysis, a significance level was set at p ≤ 0.05.

Results

Overall, these tumors were more prevalent in women (n = 37). The mean age of these patients was 58-year-old and the parotid gland was the most affected anatomic site (n = 33). All cases of AdCC and MEC showed immunopositivity to cyclin D1; however, 39.5% of the PAs were negative (p < 0.001). Regarding COX-2 immunoexpression, we observed that all cases of CME were positive, whereas 60.5% of the PA and 75% of the CAC analyzed were completely negative (p = 0.042).

Conclusions

The overexpression of COX-2, observed only in MEC, emphasizes that salivary gland tumors have different profiles. Cyclin D1 is more immunoexpressed in malignant tumors. Together, these immunohistochemical findings may be useful in differentiating the studied tumors.

Seethala RR, Stenman G (2017) Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: tumors of the salivary gland. Head Neck Pathol 11(1):55–67. https://doi.org/10.1007/s12105-017-0795-0 CrossRefPubMedPubMedCentral

Valstar MH, de Ridder M, van den Broek EC, Stuiver MM, van Dijk BAC, van Velthuysen MLF, Balm AJM, Smeele LE (2017) Salivary gland pleomorphic adenoma in the Netherlands: a nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol 66:93–99. https://doi.org/10.1016/j.oraloncology.2017.01.004 CrossRefPubMed

Andisheh-Tadbir A, Dehghani-Nazhvani A, Ashraf MJ, Khademi B, Mirhadi H, Torabi-Ardekani S (2016) MTA1 expression in benign and malignant salivary gland tumors. Iran J Otorhinolaryngol 28:51–59PubMedPubMedCentral

Jour G, West K, Ghali V, Shank D, Ephrem G, Wenig BM (2013) Differential expression of p16(INK4A) and cyclin D1 in benign and malignant salivary gland tumors: a study of 44 Cases. Head Neck Pathol 7(3):224–231. https://doi.org/10.1007/s12105-012-0417-9 CrossRefPubMedPubMedCentral

John RR, Malathi N, Ravindran C, Anandan S (2017) Mini review: multifaceted role played by cyclin D1 in tumor behavior. Indian J Dent Res 28(2):187–192. https://doi.org/10.4103/ijdr.IJDR_697_16 CrossRefPubMed

Liu Y, Sun H, Hu M, Zhang Y, Chen S, Tighe S, Zhu Y (2017) The role of cyclooxygenase-2 in colorectal carcinogenesis. Clin Colorectal Cancer 16(3):165–172. https://doi.org/10.1016/j.clcc.2016.09.012 CrossRefPubMed

Pang LY, Hurst EA, Argyle DJ (2016) Cyclooxygenase-2: a role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int 2016:2048731CrossRefPubMedPubMedCentral

Yang G, Deng Q, Fan W, Zhang Z, Xu P, Tang S, Wang P, Wang J, Yu M (2017) Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma. PLoS One 12(3):e0173641. https://doi.org/10.1371/journal.pone.0173641 CrossRefPubMedPubMedCentral

Xu F, Li M, Zhang C, Cui J, Liu J, Li J, Jiang H (2017) Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget 8(4):6003–6012. https://doi.org/10.18632/oncotarget.13990 CrossRefPubMed

10.

Liu B, Wen JK, Li BH, Fang XM, Wang JJ, Zhang YP, Shi CJ, Zhang DQ, Han M (2011) Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis 2:e185. https://doi.org/10.1038/cddis.2011.64 CrossRefPubMedPubMedCentral

11.

Chae SW, Sohn JH, Kim DH, Choi YJ, Park YL, Kim K, Cho YH, Pyo JS, Kim JH (2011) Overexpressions of cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications. Yonsei Med J 52(3):445–453. https://doi.org/10.3349/ymj.2011.52.3.445 CrossRefPubMedPubMedCentral

12.

Lee EY, Kang JY, Kim KW (2015) Expression of cyclooxygenase-2, peroxiredoxin I, peroxiredoxin 6 and nuclear factor-κB in oral squamous cell carcinoma. Oncol Lett 10(5):3129–3136CrossRefPubMedPubMedCentral

13.

Solomon MC, Vidyasagar MS, Fernandes D, Guddattu V, Mathew M, Shergill AK, Carnelio S, Chandrashekar C (2016) The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study. Med Oncol 33(12):138CrossRefPubMed

14.

Akrish S, Peled M, Ben-Izhak O, Nagler RM (2009) Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol 45(12):1044–1050. https://doi.org/10.1016/j.oraloncology.2009.07.016 CrossRefPubMed

15.

Tian Z, Li L, Wang L, Hu Y, Li J (2010) Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39(3):235–242. https://doi.org/10.1016/j.ijom.2009.10.016 CrossRefPubMed

16.

Gao M, Hao Y, Huang MX, Ma DQ, Chen Y, Luo HY, Gao Y, Cao ZQ, Peng X, Yu GY (2017) Salivary gland tumours in a northern Chinese population: a 50-year retrospective study of 7190 cases. Int J Oral Maxillofac Surg 46(3):343–349. https://doi.org/10.1016/j.ijom.2016.09.021 CrossRefPubMed

17.

Bolat Kucukzeybek B, Vedat Bayoglu I, Kucukzeybek Y, Alacacioglu A, Yigit S, Akder Sari A, Akyol M, Oktay Tarhan M (2017) The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer. J BUON 22(4):947–952PubMed

18.

Kumar B, Yadav A, Brown NV, Zhao S, Cipolla MJ, Wakely PE, Schmitt AC, Baiocchi RA, Teknos TN, Old M, Kumar P (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patientsand is inversely associated with p16-status. Oncotarget 8(9):14847–14859. https://doi.org/10.18632/oncotarget.14682 CrossRefPubMedPubMedCentral

19.

Qu K, Wang Z, Fan H, Li J, Liu J, Li P, Liang Z, An H, Jiang Y, Lin Q, Dong X, Liu P, Liu C (2017) MCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma. Cell Death Dis 8(2):e2603. https://doi.org/10.1038/cddis.2016.352 CrossRefPubMedPubMedCentral

20.

Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC (2017) Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene 36(36):5219. https://doi.org/10.1038/onc.2017.203 CrossRefPubMedPubMedCentral

21.

Patel RS, Rose B, Bawdon H, Hong A, Lee CS, Fredericks S, Gao K, O’Brien CJ (2007) Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 51(5):691–696CrossRef

22.

Hugo HJ, Saunders C, Ramsay RG, Thompson EW (2015) New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia 20(3–4):109–119. https://doi.org/10.1007/s10911-015-9333-4 CrossRefPubMed

23.

Zhou X, Shi X, Ren K, Fan GT, Wu SJ, Zhao JN (2015) Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. Eur Rev Med Pharmacol Sci 19(21):4087–4097PubMed

24.

Kuźbicki Ł, Lange D, Stanek-Widera A, Chwirot BW (2016) Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma. Melanoma Res 26(5):448–456. https://doi.org/10.1097/CMR.0000000000000282 CrossRefPubMed

25.

Whynott RM, Manahan P, Geisler JP (2016) Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer. Eur J Gynaecol Oncol 37(2):164–166PubMed

26.

Wang D, Guo XZ, Li HY, Zhao JJ, Shao XD, Wu CY (2014) Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis. Tumour Biol 35(10):10301–10307. https://doi.org/10.1007/s13277-014-2260-y CrossRefPubMed

27.

Song J, Su H, Zhou YY, Guo LL (2014) Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig Dis Sci 59(2):436–445. https://doi.org/10.1007/s10620-013-2917-1 CrossRefPubMed

28.

Turk HM, Camci C, Sevinc A, Bukyukberber S, Sari I, Adli M (2012) Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev 13(1):315–318CrossRefPubMed

29.

Lee JW, Park JH, Suh JH, Nam KH, Choe JY, Jung HY, Chae JY, Moon KC (2012) Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol 46(3):237–245. https://doi.org/10.4132/KoreanJPathol.2012.46.3.237 CrossRefPubMedPubMedCentral

30.

Cho NP, Han HS, Soh Y, Son HJ (2007) Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma. J Oral Pathol Med 36(5):297–303CrossRefPubMed

31.

Shishodia S, Koul D, Aggarwal BB (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173:2011–2022CrossRefPubMed

Titel: Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
verfasst von: Jefferson da Rocha Tenório
Leorik Pereira da Silva
Marília Gabriela de Aguiar Xavier
Thalita Santana
George João Ferreira do Nascimento
Ana Paula Veras Sobral
Publikationsdatum: 12.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 9/2018
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-018-5058-5

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Bioelectrical phase angle at diagnosis as a prognostic factor for survival in advanced head and neck cancer

Temporary olfactory improvement in chronic rhinosinusitis with nasal polyps after treatment

In reference to ‘Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion’

Cholesteatoma vs granulation tissue: a differential diagnosis by DWI-MRI apparent diffusion coefficient

Epithelial hyperplasia is responsible for the compensatory enlargement of remaining thyroid lobe after thyroidectomy

Organ preservation vs primary surgery in the management of T3 laryngeal and hypopharyngeal cancers

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO